Production (Stage)
10x Genomics, Inc.
TXG
$8.17
-$0.37-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 154.88M | 165.02M | 151.65M | 153.10M | 141.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 154.88M | 165.02M | 151.65M | 153.10M | 141.01M |
| Cost of Revenue | 49.44M | 54.07M | 45.26M | 48.88M | 47.79M |
| Gross Profit | 105.45M | 110.96M | 106.39M | 104.22M | 93.21M |
| SG&A Expenses | 89.73M | 93.83M | 81.70M | 83.04M | 84.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 203.41M | 214.86M | 193.14M | 194.84M | 200.40M |
| Operating Income | -48.53M | -49.84M | -41.49M | -41.74M | -59.40M |
| Income Before Tax | -33.51M | -48.38M | -34.44M | -37.08M | -57.80M |
| Income Tax Expenses | 852.00K | 648.00K | 1.32M | 818.00K | 2.15M |
| Earnings from Continuing Operations | -34.36M | -49.03M | -35.75M | -37.90M | -59.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.36M | -49.03M | -35.75M | -37.90M | -59.95M |
| EBIT | -48.53M | -49.84M | -41.49M | -41.74M | -59.40M |
| EBITDA | -40.51M | -41.09M | -32.52M | -32.77M | -50.20M |
| EPS Basic | -0.28 | -0.40 | -0.30 | -0.32 | -0.50 |
| Normalized Basic EPS | -0.22 | -0.25 | -0.18 | -0.19 | -0.29 |
| EPS Diluted | -0.28 | -0.40 | -0.30 | -0.32 | -0.50 |
| Normalized Diluted EPS | -0.22 | -0.25 | -0.18 | -0.19 | -0.29 |
| Average Basic Shares Outstanding | 122.61M | 121.60M | 120.73M | 120.07M | 119.39M |
| Average Diluted Shares Outstanding | 122.61M | 121.60M | 120.73M | 120.07M | 119.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |